Company Profile
Inovio Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- INO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.13 USD (-1.74%)
Close
Last updated: October 6, 2026
99.6M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, INO closed down 1.74% at $1.13. No new same-company headline was identified in the current news window.
Company overview
DNA-Medicine Biotechnology Company
INOVIO develops DNA medicines intended to generate targeted immune responses against HPV-related diseases, cancer, and infectious diseases. Its approach combines optimized plasmid DNA constructs with proprietary electroporation-based delivery devices.
CELLECTRA Delivery Technology
CELLECTRA devices deliver brief electrical pulses at the administration site to help cells take up plasmid DNA. The platform is designed to generate antigen-specific T-cell and antibody responses while avoiding viral vectors and allowing repeat dosing.
INO-3107 for Recurrent Respiratory Papillomatosis
INO-3107 is the company's lead DNA medicine and is under FDA review for recurrent respiratory papillomatosis, an HPV-driven disease characterized by recurring airway tumors and repeated surgeries. The treatment is designed to stimulate immune responses against HPV-6 and HPV-11 antigens.
VGX-3100 Partnered Program
VGX-3100 is being developed by partner ApolloBio in China for cervical high-grade squamous intraepithelial lesions associated with HPV-16 and HPV-18. The program extends INOVIO's DNA-medicine platform into precancerous cervical disease.
Next-Generation DMAb and DPROT Platforms
INOVIO is also researching DNA-encoded monoclonal antibodies and DNA-encoded proteins. These programs use administered DNA as instructions for the body to produce therapeutic proteins, potentially broadening the platform beyond conventional vaccine-like immune activation.
Future catalysts
- FDA PDUFA decision for INO-3107 in recurrent respiratory papillomatosis on October 30, 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inovio Pharmaceuticals (INO)?
Inovio Pharmaceuticals (INO) most recently closed at 1.13 USD, a -1.74% move versus the previous session.
What is the market cap of Inovio Pharmaceuticals (INO)?
Inovio Pharmaceuticals currently has a market capitalization of 99.6M USD on BioPharmSignal.
What does Inovio Pharmaceuticals do?
DNA-Medicine Biotechnology Company INOVIO develops DNA medicines intended to generate targeted immune responses against HPV-related diseases, cancer, and infectious diseases. Its approach combines optimized plasmid DNA constructs with proprietary electroporation-based delivery devices. CELLECTRA Delivery Technology CELLECTRA devices deliver brief electrical...
On which exchange is INO stock listed?
Inovio Pharmaceuticals (INO) is associated with NASDAQ, United States, Biopharma.
What is INO-3107?
FDA PDUFA decision for INO-3107 in recurrent respiratory papillomatosis on October 30, 2026.
Which conditions is Inovio Pharmaceuticals targeting with INO-3107?
Inovio Pharmaceuticals is associated with cancer therapeutics, respiratory disease based on its company overview and current catalyst commentary.
How does Inovio Pharmaceuticals describe recent progress with INO-3107?
FDA PDUFA decision for INO-3107 in recurrent respiratory papillomatosis on October 30, 2026.
What is HPV-6?
The treatment is designed to stimulate immune responses against HPV-6 and HPV-11 antigens.